Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use

Diabetes Therapy

Volumn 8, Issue 2, 2017, Pages 365-376

  McGovern, Andrew ^a   Feher, Michael ^b,c   Munro, Neil ^a   de Lusignan, Simon ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^c UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Cardiovascular disease; Cross sectional analysis; EMPA REG OUTCOME; Empagliflozin; SGLT2; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; INSULIN; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RACE; UNSTABLE ANGINA PECTORIS;

EID: 85016955978     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-017-0254-7     Document Type: Article

References (40)

1. Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.
2. Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.
3. Fujita Y, Inagaki N. Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: clinical data and mechanism of action. J Diabetes Investig. 2014;5(3):265–75.
4. Rahmoune H, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005;54(12):3427–34.
5. Johnsson K, et al. Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials. Postgrad Med. 2016;128(4):346–55.
6. Daousi C, et al. Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgrad Med J. 2006;82(966):280–4.
7. Sarafidis PA, Tsapas A. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2016;374(11):1092–4.
8. Fischereder M, Schönermarck U. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2016;374(11):1092–4.
9. Scheen AJ. Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: comparison with classic diuretics. Diabetes Metab. 2016;42(4):224–33.
10. Abdul-Ghani M, et al. SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study. Diabetes Care. 2016;39(5):717–25.
11. Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis. Diabetes Care. 2016;39:1108–14.
12. Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care. 2016;39(7):1115–22.
13. Abdul-Ghani M, et al. SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study. Diabetes Care. 2016;39(5):717–25.
14. de Lusignan S, Crawford L, Munro N. Creating and using real-world evidence to answer questions about clinical effectiveness. J Innov Health Inform. 2015;22(3):368–73.
15. McGovern A, Hinchliffe R, Munro N, de Lusignan S. Basing approval of drugs for type 2 diabetes on real world outcomes. BMJ. 2015;351:h5829.
16. McGovern A, et al. Sodium-glucose co-transporter-2 (SGLT2) inhibitors: comparing trial and real world use (study protocol). Diabetes Ther. 2017. doi:10.1007/s13300-017-0229-81–9.
17. de Lusignan S, van Weel C. The use of routinely collected computer data for research in primary care: opportunities and challenges. Fam Pract. 2006;23(2):253–63.
18. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–53.
19. de Lusignan S. Codes, classifications, terminologies and nomenclatures: definition, development and application in practice. Inform Prim Care. 2005;13(1):65–70.
20. Liaw ST, et al. Integrating electronic health record information to support integrated care: practical application of ontologies to improve the accuracy of diabetes disease registers. J Biomed Inform. 2014;52:364–72.
21. McGovern A, et al. Real-world evidence studies into treatment adherence, thresholds for intervention and disparities in treatment in people with type 2 diabetes in the UK. BMJ Open. 2016;6(11):e012801.
22. Medical Research Council and NHS Health Research Authority. Is my study research? 2016. http://www.hra-decisiontools.org.uk/research/. Accessed Dec 2016.
23. AstraZeneca. Farxiga (Dapagliflozin) [package insert]. Wilmington: AstraZeneca Pharmaceuticals LP; 2016.
24. Boehringer Ingelheim Pharmaceuticals Inc. Jardiance (Empagliflozin) [package insert]. Ridgefield: Eli Lilly and Company; 2016.
25. Janssen Pharmaceuticals Inc. Invokana (Canagliflozin) [package insert]. Titusville: Janssen Pharmaceuticals Inc.; 2016.
26. Cove-Smith A, Almond M. Management of urinary tract infections in the elderly. Trends Urol Gynaecol Sex Health. 2007;12(4):31–4.
27. Sehgal V, et al. Management of diabetes mellitus in the elderly with canagliflozin: a newer hypoglycemic drug on the horizon. J Pharmacol Pharmacother. 2014;5(4):227–31.
28. AstraZeneca. Multicenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events (DECLARE-TIMI58). 2012. https://clinicaltrials.gov/ct2/show/NCT01730534. Accessed Dec 2016.
29. Janssen Research & Development LLC. CANVAS—CANagliflozin cardioVascular Assessment Study (CANVAS). 2009. https://clinicaltrials.gov/ct2/show/NCT01032629. Accessed Dec 2016.
30. Vasilakou D, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159(4):262–74.
31. NICE. Dapagliflozin in combination therapy for treating type 2 diabetes. NICE technology appraisal guidance [TA288]. 2013.
32. NICE. Canagliflozin in combination therapy for treating type 2 diabetes. NICE technology appraisal guidance [TA315]. 2014.
33. NICE. Empagliflozin in combination therapy for treating type 2 diabetes. NICE technology appraisal guidance [TA336]. 2015.
34. Sabale U, et al. Cost-effectiveness of dapagliflozin (Forxiga(R)) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Prim Care Diabetes. 2015;9(1):39–47.
35. van Haalen HG, et al. Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands. Clin Drug Investig. 2014;34(2):135–46.
36. Lopez JM, et al. Evaluating drug cost per response with SGLT2 inhibitors in patients with type 2 diabetes mellitus. Am Health Drug Benefits. 2015;8(6):309–18.
37. Arnold SV, et al. Defining the potential “real-world” impact of the EMPA-REG OUTCOME trial on improving cardiovascular outcomes: observations from the Diabetes Collaborative Registry (DCR). Diabetologia. 2016;59(S1):347.
38. Correa A, et al. Royal College of General Practitioners Research and Surveillance Centre (RCGP RSC) sentinel network: a cohort profile. BMJ Open. 2016;6(4):e011092.
39. de Lusignan S, et al. Routinely collected general practice data: goldmines for research? A report of the European Federation for Medical Informatics Primary Care Informatics Working Group (EFMI PCIWG) from MIE2006, Maastricht, the Netherlands. Inform Prim Care. 2006;14(3):203–9.
40. de Lusignan S, et al. Routinely-collected general practice data are complex, but with systematic processing can be used for quality improvement and research. Inform Prim Care. 2006;14(1):59–66.